Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643572 | 0.79 | SCN9A (0.36) | L3MBTL1SCN9AMEN1KMT2A | |
| SCHEMBL9788146 | 0.74 | HCRTR1 (0.39) | L3MBTL1MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL5381803 | 0.71 | RORC (0.38) | MAPTALDH1A1 | |
| SCHEMBL5371737 | 0.67 | LMNA (0.52) | TDP1GAAMEN1TSHRKMT2A | |
| SCHEMBL8782262 | 0.63 | RECQL (0.36) | GAAHPGDUSP2MAPTALDH1A1 | |
| SCHEMBL5376606 | 0.63 | KMT2A (0.42) | GAAMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9258172 | 0.62 | RORC (0.35) | L3MBTL1GAAMEN1HPGDKMT2A | |
| SCHEMBL9851965 | 0.62 | TSHR (0.44) | L3MBTL1GAAHPGDTSHRKMT2A | |
| Isobutane SCHEMBL27839933 | 0.62 | TDP1 (0.54) | L3MBTL1TDP1NOTUMMEN1HPGD | |
| SCHEMBL7312272 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | PTPN1 998/4885L3MBTL1 4715/4885TDP1 2373/4885 |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | PTPN1 998/4885L3MBTL1 4715/4885TDP1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.